Healing the Vasculature: Angioprotective Therapy Moves From the Bench to the Clinic

摘要: Abstract Advances in immunosuppression have extended the lifetime of most types organ grafts, leading to improved long-term outcomes after transplantation. The fact that death transplant patient with a functioning graft currently represents cause late loss is sometimes viewed as testament this success. However, interpretation misleading because often results from systemic effects immunosuppressive treatment. Prominent among latter are atherosclerosis, infection, and malignancy. Vascular disease, manifesting arteriopathy, also contributes chronic allograft failure, another major loss. Overall, arteriosclerosis (systemic specific) accounts for about 50% loss, making it compelling therapeutic priority has yet be effectively tackled clinic. advent novel compounds angioprotective properties tighter control metabolic risk factors vascular disease potential overcome obstacle further improve outcomes. Targeted modulation growth factor hormone receptor activity by nonimmunosuppressive, low-molecular-weight complementary approach problem. Here we trace development assess promising therapies in, or approaching, clinic outline structured rationale their efficient evaluation.